Puma Biotechnology Stock Price

-0.48 (-4.23%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Puma Biotechnology Inc PBYI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.48 -4.23% 10.87 00:00:11
Open Price Low Price High Price Close Price Prev Close
11.35 10.80 11.50 10.87 11.35
Bid Price Ask Price Spread News
9.54 13.99 4.45 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,040 423,495 $ 11.05 $ 4,681,679 275,225 7.48 - 14.14
Last Trade Time Type Quantity Stock Price Currency
16:01:24 formt 60,125 $ 10.87 USD

Puma Biotechnology Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 438.73M 40.36M 33.77M $ 225.11M $ -20.28M -1.52 -16.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -11.73k 12.90%

more financials information »

Puma Biotechnology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PBYI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.1711.9510.8011.45284,274-0.30-2.69%
1 Month10.1511.959.8710.85245,0930.727.09%
3 Months10.9311.958.9910.14280,620-0.06-0.55%
6 Months11.0514.148.9910.92352,970-0.18-1.63%
1 Year9.2514.147.4810.44546,3341.6217.51%
3 Years50.7565.455.5017.901,054,695-39.88-78.58%
5 Years31.25136.905.5033.921,034,496-20.38-65.22%

Puma Biotechnology Description

Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.

Your Recent History
Puma Biote..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.